An experimental kidney cancer drug made by Pfizer didn't extend the time in which patients survived without their disease worsening when compared with a competing drug, according to results of a late-stage clinical trial released Wednesday.
A 30% rise in attendance at the Armada Specialty Pharmacy Summit is nothing to brush off — it's as clear an indication as any that specialty pharmacy is growing and probably poised for more growth in the near future, thanks in particular to the aging population and consequential rise in the number of people living with difficult-to-treat medical conditions.
As part of a nationwide effort to help communities fight congestion, Pfizer Consumer Healthcare is partnering with the Ohio Association of Police Athletic & Activities League to create more space for the local mentorship program.
Drug maker Genzyme plans to present data from trial programs of two multiple sclerosis drugs at the American Academy of Neurology's annual meeting in New Orleans, which starts this Saturday and lasts until next Saturday.
The U.S. over-the-counter drug market saw strong growth in 2011, thanks to switches of prescription drugs to OTC, gains in the allergy relief products category and holistic marketing, according to a new report from Kline.
The Consumer Healthcare Products Association on Friday morning honored longtime industry veteran Pat Lonergan, co-founder of Numark Labs, with its Ivan D. Combe Lifetime Achievement Award for his contributions in the advancement of the business of over-the-counter medicines.
According to two new surveys of parents and pediatricians from Pfizer Consumer Healthcare, more than half of all parents reported feeling anxious, fearful or helpless when their child comes down with a fever.
The Food and Drug Administration has approved a drug made by Merck for Type 2 diabetes, the drug maker said. Merck announced the approval of Janumet XR (sitagliptin and metformin hydrochloride) extended-release tablets as a once-daily treatment for the disease.